NCT01239355终止2 期
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 22
- 主要终点
- Progression-free Survival
研究概览
简要总结
This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy. MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. Evaluate the median progression-free survival in patients with advanced hepatocellular carcinoma treated with MK-2206 after failure of one prior line of anti-angiogenic therapy.
SECONDARY OBJECTIVES:
I. Evaluate the objective response rate (CR + PR). II. Evaluate the median overall survival. III. Evaluate the tolerability and toxicity profile of MK-2206 in this patient population.
IV. Explore, in a preliminary fashion, potential molecular predictors of efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable or metastatic HCC for which standard curative measures do not exist
- •The diagnosis of hepatocellular carcinoma should be based on at least one of the following:
- •The presence of one or more liver lesions, measuring >= 2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or hepatitis B or C infection
- •The presence of liver lesion(s) with AFP >= 400
- •Tissue confirmation in the absence of either or both of the above
- •Tissue availability is desired and will be sought, but tissue availability is not mandated for accrual to the study
- •Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension, and that has not been the target of local or regional therapy including transarterial chemoembolization, intra-arterial chemotherapy, ethanol, or RFA ablation
- •One prior line of systemic anti-angiogenic therapy is required; this type of therapy includes, but is not restricted to, sorafenib, bevacizumab, sunitinib, or brivanib given as single agents or in combination with other agents
- •No clinically evident ascites (minimal, medically controlled ascites detectable on imaging studies only is allowed)
- •No Child-Pugh C cirrhosis or Child-Pugh B cirrhosis with more than 7 points
- •No fibrolamellar carcinoma or any mixed variants of HCC with dominant fibrolamellar histology
- •Patients with known brain metastases should be excluded from this clinical trial
- •Life expectancy of greater than 3 months
- •Leukocytes >= 3,000/mcL
- •Absolute neutrophil count > 1,000 mcL
- •Platelets >= 70,000/mcL
- •Total bilirubin =< 1.5 institutional upper limit of normal
- •AST (SGOT)/ALT (SGPT) < 5 x institutional upper limit of normal
- •Creatinine within normal institutional limits OR creatinine clearance >= 60 mL/min
- •Serum albumin >= 2.8 g/dL
- •Not pregnant or nursing
- •Fertile patients must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
- •Must agree to collection of correlative blood samples during the study
- •No patients unable to swallow pills or diagnosed with a gastrointestinal disorder that is likely to interfere with the absorption of MK-2206 or with the patient's ability to take regular oral medication
- •Patients with hyperglycemia should be well controlled on oral agents before the patient enters the trial
- •Patients with HgbA1C levels >= 8% or fasting blood glucose >= 150 mg/dL are not eligible for this study
- •Baseline QTcF > 450 msec (male) or QTcF> 470 msec (female) will exclude patients from entry on study
- •Patients with hepatitis B infection, defined by a positive hepatitis B surface antigen test, should be on suppressive anti-viral therapy
- •Only the following anti-viral therapies are allowed while a patient is on study: tenofovir disoproxil fumarate and entecavir
- •Patients with hypothyroidism must be on a stable dose of thyroid replacement and be clinically euthyroid
- •No esophageal or gastric variceal bleeding within the last 6 months
- •Patients with prior history of variceal bleeding must have had an upper endoscopy (EGD) with appropriate treatment of varices within 6 months prior to study entry
- •No uncontrolled intercurrent illness including, but not limited to:
- •Ongoing or active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris
- •Cardiac arrhythmia
- •Psychiatric illness/social situations that would limit compliance with study requirements
- •None of the following:
- •Uncontrolled hypertension (systolic BP > 150 or diastolic BP > 100 on two occasions within two weeks of beginning therapy on this protocol)
- •Myocardial infarction within 6 months
- •NYHA class > II
- •Clinically significant bradycardia related to underlying cardiac disease
- •Clinically significant bundle branch block related to underlying cardiac disease
- •No patients with second primary cancer (except adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors including lymphomas without bone marrow involvement curatively treated with no evidence of disease for ≥ 5 years)
- •The exception to this criterion is prostate cancer treated definitively with surgery and/or radiation with normal PSA and no clinical evidence of residual or recurrent prostate cancer
- •HIV-positive patients on combination antiretroviral therapy are ineligible
- •No history of allergic reactions attributed to compounds of similar chemical orbiologic composition to MK-2206 or other agents used in the study
- •No medications that cause QTc interval prolongation
- •Any number of prior regional therapies with transarterial chemoembolization, intra-arterial chemotherapy, or ablative therapy is allowed
- 另有 7 项未显示
排除标准
- 未提供
研究组 & 干预措施
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Akt Inhibitor MK2206 (Drug)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
结局指标
主要结局
Progression-free Survival
时间窗: Until disease progression or death, up to 26 months
Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions.
次要结局
- Objective Response(Evaluated for response every 2 cycles (8 weeks) with confirmatory evaluation at least 4 weeks following initial documentation of objective response, up to 26 months)
- Overall Survival(Until death, up to 26 months)
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaRecurrent Oral Cavity Adenoid Cystic CarcinomaRecurrent Salivary Gland CarcinomaSalivary Gland Adenoid Cystic CarcinomaStage IVA Major Salivary Gland Cancer AJCC v7Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVB Major Salivary Gland Cancer AJCC v7Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVC Major Salivary Gland Cancer AJCC v7Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7NCT01604772National Cancer Institute (NCI)16
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck CancerRecurrent Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the NasopharynxNCT01349933National Cancer Institute (NCI)21
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type AdenocarcinomaGastric Mixed AdenocarcinomaRecurrent Gastric CarcinomaNCT01260701National Cancer Institute (NCI)75
已完成
2 期
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)PANCREASNeuroendocrineNCT01169649Memorial Sloan Kettering Cancer Center11
终止
2 期
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast CancerEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu NegativeHER2/Neu PositiveProgesterone Receptor NegativeProgesterone Receptor PositiveStage IA Breast CancerStage IB Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerTriple-Negative Breast CarcinomaNCT01319539National Cancer Institute (NCI)12